Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation
Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation
复制标题
DOI：
10.1161/circep.110.958033
复制
发表时间：
2011-02-01
影响因子：
8.4
通讯作者：
Burk, Caroline
中科院分区：
文献类型：
--
作者：
Spertus, John;Dorian, Paul;Burk, Caroline
背景-心房颤动（AF）对健康相关的生活质量（HRQoL）有有害影响，但测量这种结果是困难的。目前尚无一种全面、有效、疾病特异性的问卷，用于测量受房颤及其治疗影响的QoL领域谱。我们开发并验证了一个20项的问卷调查，房颤对生活质量的影响（AFEQT），在6个中心，前瞻性，observational study.Methods和结果因素分析建立了4个概念域（症状，日常活动，治疗关注，治疗满意度），从个人域和全球的分数计算。来自6个中心的受试者在基线、第1个月和第3个月完成了AFEQT。心理测量学分析包括内部一致性和已知组效度。通过比较那些治疗没有改变的患者1个月内评分的变化来评估重测信度。效应量用于评估干预后的反应性。在219例年龄为62 ± 11.9岁的患者中，94%在基线和3个月时完成了AFEQT; 66%为阵发性AF，24%为持续性AF，5%为长期持续性AF，5%为永久性AF。所有量表的内部一致性均> 0.88。观察到AF严重程度增加时AFEQT评分降低，分类为无症状、轻度、中度和重度，分别为：71.2 +/- 20.6、71.3 +/- 19.2、57.9 +/- 19.0和42.0 +/- 21.2。总体、症状、日常活动、治疗关注和满意度评分的组内相关性分别为0.8、0.5、0.8、0.7和0.7。消融后3个月评分的变化大于药理学调整，且均大于在稳定patients. Conclusions中观察到的变化，AFEQT的初步验证支持其作为研究结果和临床随访AF患者的一种手段。2011;4：15-25.）
Background-Atrial fibrillation (AF) has a deleterious impact on health-related quality-of-life (HRQoL), but measuring this outcome is difficult. A comprehensive, validated, disease-specific questionnaire to measure the spectrum of QoL domains affected by AF and its treatment is not available. We developed and validated a 20-item questionnaire, Atrial Fibrillation Effect on QualiTy-of-life (AFEQT), in a 6-center, prospective, observational study.Methods and Results-Factor analyses established 4 conceptual domains (Symptoms, Daily Activities, Treatment Concern, and Treatment Satisfaction) from which individual domain and global scores were calculated. Participants from 6 centers completed the AFEQT at baseline, at month 1, and at month 3. Psychometric analyses included internal consistency and known-group validity. Test-retest reliability was assessed by comparing 1-month changes in scores among those with no change in therapy. Effect size was used to assess responsiveness after intervention. Among 219 patients age 62 +/- 11.9 years, 94% completed the AFEQT at baseline and 3 months; 66% had paroxysmal, 24% persistent, 5% longstanding persistent, and 5% permanent AF. Internal consistency was > 0.88 for all scales. Lower AFEQT scores were observed with increased AF severity, categorized as asymptomatic, mild, moderate and severe, respectively: 71.2 +/- 20.6, 71.3 +/- 19.2, 57.9 +/- 19.0, and 42.0 +/- 21.2. Intraclass correlations for Overall, Symptoms, Daily Activities, Treatment Concern, and Satisfaction scores were 0.8, 0.5, 0.8, 0.7, and 0.7, respectively. Changes in 3-month scores were larger after ablation than with pharmacological adjustments, and both were greater than those observed in stable patients.Conclusions-This initial validation of AFEQT supports its use as an outcome in studies and a means to clinically follow patients with AF. (Circ Arrhythm Electrophysiol. 2011;4:15-25.)